Bakay U, İzci Duran T. Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort. Archives of Rheumatology [Internet]. 2025 Dec. 1 [cited 2025 Dec. 5];40(4):465-73. Available from: https://www.anadolupsikiyatri.net/index.php/pub/article/view/1520